416 related articles for article (PubMed ID: 18469801)
1. PML targeting eradicates quiescent leukaemia-initiating cells.
Ito K; Bernardi R; Morotti A; Matsuoka S; Saglio G; Ikeda Y; Rosenblatt J; Avigan DE; Teruya-Feldstein J; Pandolfi PP
Nature; 2008 Jun; 453(7198):1072-8. PubMed ID: 18469801
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
[TBL] [Abstract][Full Text] [Related]
3. Molecular targeting therapy against promyelocytic leukemia protein using arsenic acids in experimental intracranial medulloblastoma.
Gu C; Yokota N; Gao Y; Amano S; Koizumi S; Tokuyama T; Namba H
Neurol Med Chir (Tokyo); 2012; 52(2):62-7. PubMed ID: 22362285
[TBL] [Abstract][Full Text] [Related]
4. The role of PML in hematopoietic and leukemic stem cell maintenance.
Nakahara F; Weiss CN; Ito K
Int J Hematol; 2014 Jul; 100(1):18-26. PubMed ID: 24488785
[TBL] [Abstract][Full Text] [Related]
5. The impact of molecularly targeted therapies upon the understanding of leukemogenesis and the role of hematopoietic stem cell transplantation in acute promyelocytic leukemia.
Nagai S; Takahashi T; Kurokawa M
Curr Stem Cell Res Ther; 2010 Dec; 5(4):372-8. PubMed ID: 20528759
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide and promyelocytic leukemia protein-adenovirus synergistically inhibit in vitro and in vivo growth of a hepatoma cell line.
Cui L; Zhang S; Zhang W; Hu Z; Cao Z; Li T
Oncol Res; 2010; 18(7):305-14. PubMed ID: 20377131
[TBL] [Abstract][Full Text] [Related]
7. The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1.
Mathieu MG; Miles AK; Ahmad M; Buczek ME; Pockley AG; Rees RC; Regad T
Cell Death Dis; 2014 Feb; 5(2):e1061. PubMed ID: 24525737
[TBL] [Abstract][Full Text] [Related]
8. Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RARalpha-positive leukemic stem cells.
Zheng X; Seshire A; Rüster B; Bug G; Beissert T; Puccetti E; Hoelzer D; Henschler R; Ruthardt M
Haematologica; 2007 Mar; 92(3):323-31. PubMed ID: 17339181
[TBL] [Abstract][Full Text] [Related]
9. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
Liu JH; Liu CC; Yen CC; Gau JP; Wang WS; Tzeng CH
Int J Cancer; 2009 Jul; 125(1):71-7. PubMed ID: 19291793
[TBL] [Abstract][Full Text] [Related]
10. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies.
Iwanami A; Gini B; Zanca C; Matsutani T; Assuncao A; Nael A; Dang J; Yang H; Zhu S; Kohyama J; Kitabayashi I; Cavenee WK; Cloughesy TF; Furnari FB; Nakamura M; Toyama Y; Okano H; Mischel PS
Proc Natl Acad Sci U S A; 2013 Mar; 110(11):4339-44. PubMed ID: 23440206
[TBL] [Abstract][Full Text] [Related]
11. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
[TBL] [Abstract][Full Text] [Related]
12. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
Isakson P; Bjørås M; Bøe SO; Simonsen A
Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
[TBL] [Abstract][Full Text] [Related]
13. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
[TBL] [Abstract][Full Text] [Related]
14. Promyelocytic leukaemia protein links DNA damage response and repair to hepatitis B virus-related hepatocarcinogenesis.
Chung YL; Wu ML
J Pathol; 2013 Aug; 230(4):377-87. PubMed ID: 23620081
[TBL] [Abstract][Full Text] [Related]
15. SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.
Fasci D; Anania VG; Lill JR; Salvesen GS
Sci Signal; 2015 Jun; 8(380):ra56. PubMed ID: 26060329
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
17. SUMOylation of HMGA2: selective destabilization of promyelocytic leukemia protein via proteasome.
Cao X; Clavijo C; Li X; Lin HH; Chen Y; Shih HM; Ann DK
Mol Cancer Ther; 2008 Apr; 7(4):923-34. PubMed ID: 18413806
[TBL] [Abstract][Full Text] [Related]
18. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
19. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
20. The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network.
Song MS; Salmena L; Carracedo A; Egia A; Lo-Coco F; Teruya-Feldstein J; Pandolfi PP
Nature; 2008 Oct; 455(7214):813-7. PubMed ID: 18716620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
